LOS ALAMOS, NM, April 29, 2020 / – Trait Biosciences Inc., a leading biotechnology research organization providing innovative technology to the hemp and cannabis industry, announced today that the U.S. Patent and Trademarks Office has allowed the company protection for
its Trait Amplified technology that increases trichome production and up-regulates production of cannabinoids.
This is the newest of more than 90 patents held, applied for, or licensed to Trait within cannabinoid research. Specifically, the patent notes that:
- Trait has identified a gene that, when expressed in a cannabis plant, increases trichome production by at least 30%, and increases total cannabinoid production by almost 200%.
- For select cannabinoids like THC and CBD, the increased production was even greater, at 400% and 300%, respectively.
“This latest patent is an important advance in protecting our commercial partners who will utilize Trait’s technology to build competitive advantage for their businesses,” said Peter McDonough, Chief Executive Officer. “In the face of the challenges of operating during the disruption of COVID-19, the Trait team remains focused on unlocking the potential and power of cannabinoids for applications across consumer and health & wellness businesses. This recent patent reflects the continued advances being led by our renown team.”
This patent allowance reflects a major advancement in hemp plant transformation led by the scientists at Trait. While other research institutions have attempted without success to metabolically engineer the Cannabis sativa plant, Trait’s achievement is the first time a hemp plant has been stably transformed and successfully grown roots and stems.
This science paves the way for Trait to commercialize its Trait Amplified technologies. Hemp plants grown under proprietary Amplified technology utilize greater photosynthetic efficiency, generate more trichomes, and can deliver cannabinoid yields that are 2x – 4x higher than conventional plants. In addition, Trait is developing proprietary technology which enables the plant to produce water-soluble cannabinoids that provide increased bioavailability and more rapid onset time than conventional plants.
About Trait Biosciences
With a team of internationally recognized scientists who are applying best-in-class technology and agricultural science, Trait Biosciences is an emerging biotechnology leader in the hemp and cannabis industries. Its consumer technology platforms provide breakthrough IP and science which produce enhanced cannabinoids featuring predictable onset timing, superior bioavailability, extended stability, and improved taste. Trait’s patent pending technologies include a process for generating water-soluble cannabinoids that does not rely on emulsion or nanotechnology. The company’s agricultural technologies increase crop yields and plant safety, including ultrahigh yield Amplified™ plants which dramatically increase a plant’s natural cannabinoid productivity, and its Defence™ RNAi crop protection technology, which eliminates the need for pesticides or fungicides, providing higher quality, safer, CBD-infused nutraceutical and pharmaceutical products.
Cautionary Statement on Forward-Looking Information
Certain information contained in this press release, including any information as to Trait Bioscience Inc.’s (the “Corporation”) strategy, projects, plans or future financial or operating performance, constitutes “forward-looking statements”. All statements, other than statements of historical fact, are forward-looking statements. The words “will”, “expect”, “continue”, “assess”, “anticipate” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions; including material estimates and assumptions that, while considered reasonable by the Corporation as at the date of this press release in light of each of management’s experience and perception of current conditions and expected developments, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information.
Any forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Although management of the Corporation believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.
Media Contacts
Colleen Rubart
Trait Biosciences
+1 (415) 283-7100
Thomas Walek
+1 (917) 353-7575
